We can identify individuals years before brain imaging detects anything
For generations, Alzheimer's disease has been met only after it has already done its deepest work — a diagnosis arriving long after the quiet unraveling has begun. Researchers at Mass General Brigham in Boston have now identified a protein marker in the blood, pTau217, that can detect the disease's earliest biological stirrings a decade or more before symptoms emerge and even before brain imaging reveals any sign of trouble. Discovered through an eight-year study of 317 cognitively healthy adults, this finding reframes Alzheimer's not as an inevitable decline to be managed, but as a process that may one day be intercepted before it takes hold.
- Alzheimer's has long outpaced medicine's ability to detect it — by the time a diagnosis arrives, years of silent brain damage have already accumulated.
- A protein fragment called pTau217, measurable through a simple blood draw, is now showing up as a warning signal years before PET scans — the previous gold standard — can detect anything abnormal.
- An eight-year Harvard study of 317 healthy adults found that elevated pTau217 levels reliably predicted who would later develop amyloid buildup and cognitive decline, even when their brains appeared completely normal on imaging.
- The FDA's recent clearance of the first Alzheimer's blood test signals the field is ready to move away from expensive PET scans and lumbar punctures toward accessible, routine screening.
- Researchers are now focused on using pTau217 as a gateway into prevention trials — enrolling at-risk people early enough that intervention might stop the disease before it ever surfaces.
For decades, Alzheimer's disease has been diagnosed only after it has already reshaped a person's world — memory slipping, faces becoming unfamiliar, the brain's structure visibly altered on a scan. By that point, the disease has often been quietly at work for years. Researchers at Mass General Brigham in Boston believe they have found a way to see it coming far sooner: not through brain imaging, but through a simple blood test.
The key is a protein fragment called phosphorylated tau 217, or pTau217. A new study showed that measuring this marker can reveal the earliest stages of Alzheimer's in people who feel entirely well — years before symptoms emerge and, critically, before anything appears on a brain scan. Lead author Hyun-Sik Yang put it plainly: pTau217 can be detected "well before clear abnormalities appear on amyloid PET scans," which were previously considered the earliest available window into the disease.
The research followed 317 cognitively healthy adults between the ages of 50 and 90 over eight years as part of the Harvard Aging Brain Study. Participants received blood tests, repeated PET scans, and cognitive assessments throughout. The results were striking: higher baseline pTau217 levels predicted faster accumulation of Alzheimer's pathology even when initial brain imaging looked completely normal. Those who began the study with low levels largely remained free of significant amyloid buildup years later.
The practical implications are significant. A blood draw is cheaper, faster, and far more accessible than a PET scan or lumbar puncture — the kind of test that could eventually become routine for older adults. The FDA's recent clearance of the first Alzheimer's blood test suggests the field is already moving in that direction. For now, researchers see pTau217 as a tool for identifying who should be enrolled in prevention trials, giving scientists a chance to test whether early intervention can slow or stop the disease before any damage becomes visible — or felt.
For decades, doctors have watched Alzheimer's disease unfold like a slow-motion catastrophe—waiting for the moment when memory begins to slip, when a person stops recognizing faces, when the brain's architecture visibly crumbles on a scan. By then, the disease has already been at work for years, sometimes decades, silently accumulating the toxic proteins that define the condition. But researchers at Mass General Brigham in Boston have now found a way to catch it far earlier: not in the brain itself, but in the blood.
The discovery centers on a protein fragment called phosphorylated tau 217, or pTau217. In a new study, scientists showed that measuring this marker in a simple blood test can reveal the earliest stages of Alzheimer's disease in people who feel and function normally—years before any symptoms emerge, and crucially, before the telltale signs show up on brain imaging. The finding represents a significant shift in how researchers think about detecting the disease, and it opens a path toward prevention rather than treatment of decline that has already taken hold.
For the past two decades, the gold standard for early detection has been PET scans, which can visualize amyloid accumulation in the brain a full decade or two before someone experiences cognitive problems. But the new work suggests that pTau217 in the blood can identify at-risk individuals even sooner. "We used to think PET scan detection was the earliest sign," said Hyun-Sik Yang, a neurologist at Mass General Brigham and lead author of the study. "But now we are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans." Yang is also an associate member of the Broad Institute of MIT and Harvard.
The research tracked 317 cognitively healthy adults, ranging in age from 50 to 90, over an average of eight years as part of the Harvard Aging Brain Study. Participants underwent blood tests measuring pTau217, repeated brain imaging with PET scans, and ongoing cognitive assessments. The scientists wanted to know whether baseline pTau217 levels—and changes in those levels over time—could predict who would later develop amyloid buildup, tau accumulation, and cognitive decline. What they found was striking: higher pTau217 levels predicted faster accumulation of Alzheimer's pathology, even when initial brain scans looked completely normal. Equally important, people who started the study with low pTau217 levels remained unlikely to develop significant amyloid buildup years later.
The timing matters enormously. Increases in pTau217 frequently occurred before amyloid PET scans turned positive, meaning the blood test caught the disease's earliest whispers before brain imaging could hear them. "Even when amyloid scans appear normal in the clinic, the pTau217 biomarker can identify individuals who later become amyloid-positive," Yang noted. "It also shows that those with low pTau217 levels are likely to stay amyloid-negative for several years." This distinction could reshape how researchers design prevention trials, allowing them to enroll people at genuine risk before irreversible damage accumulates.
The timing of this discovery is fortuitous. Last year, the FDA cleared the first blood test for Alzheimer's disease, signaling that the field is ready to move beyond expensive, invasive procedures like lumbar punctures and PET scans. A simple blood draw is cheaper, faster, and far more accessible—the kind of test that could eventually become part of routine health screening for older adults. Jasmeer Chhatwal, a co-senior author and neurologist at Mass General Brigham, emphasized the potential: "By anticipating who's going to turn amyloid-positive in the future, we are trying to push back the clock to enable earlier Alzheimer's disease prediction."
Yang and his colleagues are careful not to overstate what comes next. The study does not yet justify recommending pTau217 testing for all older adults. But they see the research as a foundation for using the blood test as a screening tool in clinical trials targeting prevention—identifying which people should be enrolled in studies testing whether early intervention can slow or stop the disease before symptoms appear. Eventually, if those prevention strategies prove effective, the test could become a standard part of preventive medicine, offering people a chance to act on their risk long before they experience decline.
Notable Quotes
We used to think PET scan detection was the earliest sign of Alzheimer's disease progression. But now we are seeing that pTau217 can be detected years earlier, well before clear abnormalities appear on amyloid PET scans.— Hyun-Sik Yang, lead author and neurologist at Mass General Brigham
By anticipating who's going to turn amyloid-positive in the future, we are trying to push back the clock to enable earlier Alzheimer's disease prediction.— Jasmeer Chhatwal, co-senior author and neurologist at Mass General Brigham
The Hearth Conversation Another angle on the story
Why does it matter that we can detect this protein years before a PET scan would show anything?
Because by the time a PET scan lights up, the disease has already been working for a decade or more. If we can identify people earlier, we have a window to intervene—maybe with drugs, maybe with lifestyle changes—before the damage becomes irreversible.
But the study didn't test whether early intervention actually works, right?
Correct. This study shows we can predict who will decline. The next step is proving that catching them early actually changes the outcome. That's what the prevention trials will test.
So someone could get this blood test today and learn they're at risk for a disease they might never develop?
Yes. That's the trade-off. Some people with high pTau217 will progress to Alzheimer's; others won't. We don't yet know how to distinguish between them, or whether knowing your risk changes anything if there's no proven prevention.
Why is blood testing cheaper than PET scans?
A PET scan requires specialized equipment, radiation, and a trained technician. A blood test is just a needle and a lab. It scales easily. You could do it at your doctor's office.
What happens to someone who tests positive?
Right now, nothing specific. The researchers say it's too early to recommend routine testing. But in a few years, if prevention trials show promise, a positive test might mean enrollment in a clinical trial, or monitoring, or lifestyle interventions.
Does this change anything for people who already have symptoms?
Not really. This is about catching asymptomatic people. Once someone has memory loss, the disease is already advanced. The value here is prevention, not treatment.